New advances in antifungal treatment

Medical Mycology

Volumn 38, Issue , 2000, Pages 317-322

  Finquelievich, Jorge L ^a   Odds, F C ^b   Queiroz Telles, F ^c   Wheat, L J ^d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspergillosis surgery; Aspergillosis therapy; Dermatiaceae treatment; Endemic mycosis treatment

Indexed keywords

4 [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 1 PIPERAZINYL]PHENYL] 2,4 DIHYDRO 2 [4 (TRIFLUOROMETHOXY)BENZYL] 1,2,4 TRIAZOL 3 ONE; AMINOGLYCOSIDE; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLODEXTRIN; CYCLOSPORIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; LIQUID NITROGEN; NIKKOMYCIN Z; POSACONAZOLE; RAVUCONAZOLE; TACROLIMUS; TERBINAFINE; TRIAZOLE; VANCOMYCIN; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CHROMOMYCOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MONITORING; DRUG POTENTIATION; DRUG SCREENING; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; LUNG ASPERGILLOSIS; MYCETOMA; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PHAEOHYPHOMYCOSIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; HUMANS; MITOSPORIC FUNGI; MYCOSES;

ASPERGILLUS; FUNGI;

EID: 0034507696     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.38.1.317.322     Document Type: Article

References (54)

1. Antifungal and surgical treatment of invasive aspergillosis: Review of 2121 published cases
2. Aspergillosis
3. Invasive aspergillosis in transplant recipients
4. Interactions between tacrolimus and antimicrobial agents
5. Cyclosporine associated renal dysfunction in marrow transplant recipients
6. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion
7. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
8. Lipid formulation of amphotericin B: Recent progress and future directions
9. Analysis of compassionate use itraconazole therapy for invasive aspergillos by the NIAID Mycosis Study Group criteria
10. NIAID Mycosis Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis
11. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients
12. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae
13. Pulmonary resection for fungal infection in children undergoing bone marrow transplantation
14. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases
15. Effect of melanin and carotenoids of Exophiala (Wangiella) dermatitidis on phagocytosis, oxidative burst, and killing by human neutrophils
16. Fungal melanins: A review
17. Confirmation of a link between fungal pigmentation, turgor pressure, and pathogenicity using a new method of turgor measurement
18. Melanins and their importance in pathogenic fungi
19. Allergic fungal sinusitis: The Mayo Clinic experience
20. Fungemia due to Exophiala jeanselmei. Report of 23 cases
21. Infections caused by dematiaceous fungi: Chromoblastomycosis and phaeohyphomycosis
22. Chromoblastomycosis and phaeohyphomycosis: New concepts, diagnosis and mycology
23. Chromomycosis
24. Treatment of chromoblastomycosis with itraconazole
25. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi
26. Traitement de quatre cas de chromomycose à Fonsecaea pedrosoi par l'association 5-fluorocytosine-itraconazole
27. Successful treatment of chromoblastomycosis due to Fonsecaea pedrosoi by combination of itraconazole and cryotherapy
28. Adrenal response to corticotrophin and testosterone during long-term therapy with itraconazole in patients with chromoblastomycosis
29. Treatment of chromomycosis with terbinafine: Preliminary results of an open pilot study
30. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis
31. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
32. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
33. Histoplasmosis: Experience during outbreaks in Indianapolis and review of the literature
34. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice
35. A multicenter randomized trial comparing amphotericin B (AmB) and liposomal amphotericin B (AmBisome, LAmB) as induction therapy of disseminated histoplasmosis (DH) in AIDS patients
36. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome
37. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome
38. Treatment of blastomycosis with higher doses of fluconazole
39. Fluconazole therapy for coccidioidal meningitis
40. Potential new antifungal agents
41. Current and emerging azole antifungal agents
42. SCH 56592 treatment of murine invasive aspergillosis
43. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.
44. Treatment of murine fusariosis with SCH 56592
45. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis
46. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
47. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo
48. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
49. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
50. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
51. Treatment of histoplasmosis with MK-0991 (L-743,872)
52. Efficacy of nikkomycin Z in the treatment of murine histoplasmosis
53. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis
54. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis